Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mather, K. J.
Right arrow Articles by Baron, A. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mather, K. J.
Right arrow Articles by Baron, A. D.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 53:2060-2066, 2004
© 2004 by the American Diabetes Association, Inc.

Interactions Between Endothelin and Nitric Oxide in the Regulation of Vascular Tone in Obesity and Diabetes

Kieren J. Mather1, Amale Lteif1, Helmut O. Steinberg1, and Alain D. Baron1,2

1 Division of Endocrinology & Metabolism, Indiana University School of Medicine, Indianapolis, Indiana
2 Amylin Pharmaceuticals, San Diego, California

Endothelial dysfunction reflects an imbalance of vasodilators and vasoconstrictors. Endogenous endothelin activity seems to be increased in human obesity and type 2 diabetes, and cellular studies suggest that this factor may itself reduce bioavailable nitric oxide (NO). We studied 20 lean, 20 obese, and 14 type 2 diabetic individuals under three protocols, measuring leg vascular responses to intra-arterial infusions of NG-monomethyl-L-arginine (L-NMMA; an inhibitor of NO synthase) alone or in combination with BQ123 (an antagonist of type A endothelin receptors) or phentolamine (used as a control vasodilator). NO synthase inhibition alone (study 1) produced an ~40% increase in leg vascular resistance (LVR) in all three participant groups, which was not statistically different across groups (increase in LVR: lean, 135 ± 28; obese, 140 ± 32; type 2 diabetic, 184 ± 51 units; NS). By design, BQ123 at the infused rate of 3 µmol/min produced equivalent ~35% reductions in LVR across groups. The subsequent addition of L-NMMA produced a greater increase in LVR among obese participants than lean or type 2 diabetic participants (study 2: lean, 182 ± 48; obese, 311 ± 66; type 2 diabetic, 186 ± 40; P = 0.07). Compared with study 1, the effect of L-NMMA was magnified by BQ123 in obese participants but not in lean or type 2 diabetic participants (P = 0.005, study 1 vs. 2; P = 0.03 for group effect). Phentolamine (75 mg/min) produced vasodilation in obese participants comparable to that seen with BQ123 but failed to augment the L-NMMA response. Endothelin antagonism unmasks or augments NO synthesis capacity in obese but not type 2 diabetic participants. This suggests that impaired NO bioavailability as a result of endogenous endothelin may contribute to endothelial dysfunction in obesity, in addition to direct vasoconstrictor effects of endothelin. In contrast, endothelin antagonism alone is insufficient to restore impaired NO bioavailability in diabetes.


Address correspondence and reprint requests to Kieren J. Mather, MD, FRCPC, Division of Endocrinology & Metabolism, Department of Medicine, Indiana University School of Medicine, CL459, 541 North Clinical Dr., Indianapolis, IN 46202. E-mail: kmather{at}iupui.edu


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Endocr. Rev.Home page
R. Muniyappa, M. Montagnani, K. K. Koh, and M. J. Quon
Cardiovascular Actions of Insulin
Endocr. Rev., August 1, 2007; 28(5): 463 - 491.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
A. Lteif, P. Vaishnava, A. D. Baron, and K. J. Mather
Endothelin Limits Insulin Action in Obese/Insulin-Resistant Humans
Diabetes, March 1, 2007; 56(3): 728 - 734.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. E. Silver, S. D. Beske, D. D. Christou, A. J. Donato, K. L. Moreau, I. Eskurza, P. E. Gates, and D. R. Seals
Overweight and Obese Humans Demonstrate Increased Vascular Endothelial NAD(P)H Oxidase-p47phox Expression and Evidence of Endothelial Oxidative Stress
Circulation, February 6, 2007; 115(5): 627 - 637.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C. Loghin, S. Sdringola, and K. L. Gould
Does coronary vasodilation after adenosine override endothelin-1-induced coronary vasoconstriction?
Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H496 - H502.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
R. H. Rosa Jr., T. W. Hein, Z. Yuan, W. Xu, M. I. Pechal, R. L. Geraets, J. M. Newman, and L. Kuo
Brimonidine evokes heterogeneous vasomotor response of retinal arterioles: diminished nitric oxide-mediated vasodilation when size goes small
Am J Physiol Heart Circ Physiol, July 1, 2006; 291(1): H231 - H238.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J.-a Kim, M. Montagnani, K. K. Koh, and M. J. Quon
Reciprocal Relationships Between Insulin Resistance and Endothelial Dysfunction: Molecular and Pathophysiological Mechanisms
Circulation, April 18, 2006; 113(15): 1888 - 1904.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. A. Potenza, F. L. Marasciulo, D. M. Chieppa, G. S. Brigiani, G. Formoso, M. J. Quon, and M. Montagnani
Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production
Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H813 - H822.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A.A. Lteif, K. Han, and K.J. Mather
Obesity, Insulin Resistance, and the Metabolic Syndrome: Determinants of Endothelial Dysfunction in Whites and Blacks
Circulation, July 5, 2005; 112(1): 32 - 38.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
K. Rahmouni, M. L.G. Correia, W. G. Haynes, and A. L. Mark
Obesity-Associated Hypertension: New Insights Into Mechanisms
Hypertension, January 1, 2005; 45(1): 9 - 14.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2004 by the American Diabetes Association.